Anhedonia as a Transdiagnostic Phenomenon: Neurobiological, Clinical, and Therapeutic Approaches

Authors

  • Paula Mirabel Révora Médica Psiquiatra. Especialista en Drogadependencias, Universidad de Tucumán. Asociación de Psiquiatras de Argentina (APSA) https://orcid.org/0009-0002-7938-4264
  • Mario Levin Médico Psiquiatra, Universidad de Buenos Aires. Magister en Neuropsicofarmacología, Universidad Favaloro. Asociación de Psiquiatras de Argentina https://orcid.org/0009-0007-7242-6827
  • Fernando Torrente Licenciado en Psicología, Universidad de Buenos Aires. Doctor en Medicina, Universidad Favaloro. Instituto de Neurociencias Cognitivas y Transicionales, CONICET, Universidad Favaloro, Fundación INECO.  https://orcid.org/0000-0001-7470-6979
  • Pedro Damián Gargoloff Médico Psiquiatra. Jefe de Sala. Hospital “Dr. Alejandro Korn”, La Plata, Argentina. Asociación de Psiquiatras de Argentina (APSA). https://orcid.org/0009-0006-6477-9959
  • María Florencia Iveli Especialista en Psiquiatría infantojuvenil. Doctora en Medicina, Universidad Nacional de La Plata. Asociación de Psiquiatras de Argentina (APSA) https://orcid.org/0009-0006-9977-3573

DOI:

https://doi.org/10.53680/vertex.v37i172.1017

Keywords:

anhedonia, treatment, psychopharmacology, psychotherapy

Abstract

Anhedonia, classically defined as the inability to experience pleasure, was introduced in 1897 by the French philosopher and psychologist Théodule Armand Ribot. Although this term is still used, it has undergone conceptual modifications because the dichotomy of the original description is insufficient to capture the complexity of its components (Pérez Rincón, 2014). The hedonic experience is a dynamic and cyclical process that begins with a state with an individual reference range, known as hedonic tone, which determines each person’s capacity to experience pleasure and happiness. Currently, anhedonia is considered a transdiagnostic, multidimensional, and dynamic construct consisting of multiple attributes or valences whose combination determines a wide variety of behavioral phenotypes. These may be transiently altered or represent a more enduring trait. The presence of anhedonia in various psychopathological disorders is associated with greater severity, a worse prognosis, and an increased risk of suicide. For this reason, effective psychotherapeutic and pharmacological treatments are essential. The objective of this paper, a narrative review, was to offer an expert clinical opinion, summarizing the evidence on some anhedonia phenotypes and their potential treatments. Three adapted clinical vignettes are also included as examples

Downloads

Download data is not yet available.

Author Biographies

Mario Levin, Médico Psiquiatra, Universidad de Buenos Aires. Magister en Neuropsicofarmacología, Universidad Favaloro. Asociación de Psiquiatras de Argentina



Fernando Torrente, Licenciado en Psicología, Universidad de Buenos Aires. Doctor en Medicina, Universidad Favaloro. Instituto de Neurociencias Cognitivas y Transicionales, CONICET, Universidad Favaloro, Fundación INECO. 

Paula Mirabel Révora

Pedro Damián Gargoloff, Médico Psiquiatra. Jefe de Sala. Hospital “Dr. Alejandro Korn”, La Plata, Argentina. Asociación de Psiquiatras de Argentina (APSA).



María Florencia Iveli, Especialista en Psiquiatría infantojuvenil. Doctora en Medicina, Universidad Nacional de La Plata. Asociación de Psiquiatras de Argentina (APSA)



Published

2026-07-10

How to Cite

Révora, P. M. ., Levin, M., Torrente, . F., Gargoloff, P. D., & Iveli, M. F. (2026). Anhedonia as a Transdiagnostic Phenomenon: Neurobiological, Clinical, and Therapeutic Approaches. Vertex Revista Argentina De Psiquiatría, 37(172, abr.-jun.), 49–71. https://doi.org/10.53680/vertex.v37i172.1017

Issue

Section

Artículos

Most read articles by the same author(s)